For the record...Bioasis's failures have not been caused by the technology. It's as infuriating to me as anyone else that this has gone on for far too long.
But at the end of the day, the LRP1 receptor is there, xB3 connects to it, drugs are transported across the BBB and the promise of effective neurotherapeutics is still alive despite all of the hubris, poor strategic plans and failed efforts to make something of it all.
It is so easy to make the case that investors should abandon Bioasis. Bioasis was first mentioned as the qualifying transaction in a press release on October 24, 2007 by the capital pool, W.R. Partners Ltd. The first press release put out by the newly-trading company, Bioasis Technologies, Inc., was on April 1, 2008. That's not 10 years ago; it's over 13 years ago. The irony of April's Fool Day, sadly, isn't remotely funny.
I've taken a lot of abuse over the years over Bioasis. I give as good as I get but it's been damn hard. I still work my nether-end off every day, trying to see where this can go, what it could be, talking investors off the ledge, trying to break through the secrets. The effing secrets are sometimes too cute by half. I have the awful list of them, announcements not made, but left to be inferred from suddenly missing references in official documents.
The recent news about xB3-004 and MS is extremely promising. Even Denali with its cumbersome F-Star Transport Vehicle is chasing the IL-1 receptor antagonist. Is there room for Bioasis? Damn right there is. In the end, there may not be room for Denali's version, no matter how much sooner they might get it to market.
But for various reasons, I have little patience left. This is the ninth inning and we're a few runs down, but the top of the lineup is due up. We can still win this, but I suspect I'll remain an angry person until it happens, hopefully in the next three months.
jd